This article reviews the promises and challenges in developing and validating biomarkers that could help HCPs distinguish DILI from other causes of liver injury and identify the causative drug.

Abstract and Introduction Current Status of DILI Biomarkers Promising Avenues for Discovery of New DILI Biomarkers Next Steps References The lymphocyte transformation test is commercially ...

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001). Article PubMed Google Scholar ...

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), drug-induced liver injury (DILI) is the leading cause of acute liver failure in the U.S. It is also a leading ...

"GLDH will allow drug developers to properly determine the onset of liver injury in clinical trials for novel therapies to treat patients with muscle disease, where the traditional DILI biomarkers may ...

CAMBRIDGE, England, June 10, 2025--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal ...

In response to growing market demand for tools that address these concerns, CN Bio has expanded the in vitro to in vivo extrapolation (IVIVE) capabilities of its established PhysioMimix ® DILI ...

New biomarkers could improve early detection and monitoring of kidney injury Date: January 6, 2025 Source: Boston Medical Center Summary: Researchers have identified six new biomarkers that could ...